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Acute acquired toxoplasmosis (AAT) has traditionally been
considered an oligosymptomatic and self-limited infection in
previously healthy patients. Immunocompetent individuals with
AAT are usually not treated unless presenting severe or persistent
symptoms.1 However, severe acute disseminated AAT in immu-
nocompetent patients has been reported in association with new
virulent strains of Toxoplasma gondii.2,3 Despite the fact that the
treatment of toxoplasmosis is well established when associated
with immunodeﬁciency,4 there are controversies concerning
treatment in AAT and ocular disease.
We read with great interest a recently released ahead-of-print
paper on a double-blind randomized clinical trial of co-trimox-
azole for the treatment of toxoplasmic lymphadenitis.5 This
pioneering work raises the question of the therapeutic manage-
ment of AAT patients and sheds new light on the subject. Our group
has been concerned with the indications for the treatment of AAT
and recently proposed a morbidity scale associated with long-
lasting disease.6
With regard to the paper by Alavi and Alavi,5 as patients were
randomized to the analysis groups and as toxoplasmosis presents a
broad range of clinical manifestations, bias could have been
introduced if more severe cases were eventually included in the
placebo group . This would be avoided by means of a stratiﬁcation
severity scale of infection, randomized in both groups. Criticism
could be raised regarding the study endpoints, based only on
clinical signs (absence of palpable lymph nodes) and serologic data
(IgM levels <6 IU), instead of clinical morbidity parameters.6
We agree with the authors that there is a need for large-scale
multicenter studies. There is a lack of studies analyzing treatment
indications as well as therapeutic regimens. Co-trimoxazole has an
easy-to-use dosage compared to the more complex and adverse-
effect-prone sulfadiazine/pyrimethamine/folinic acid regimen.1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.08.003We look forward to future clinical trials in toxoplasmosis, not
only in AAT, but also in ocular and prenatal infection, for which we
currently have more questions than answers.
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